BMC cancer

How the body’s internal clock may influence the success of immune checkpoint treatments in solid tumors

Updated

Abstract

Early infusion of anti-PD-1 or anti-PD-L1 therapy resulted in a 49% disease control rate compared to 40% for late infusion.

  • Higher disease control rate (DCR) was associated with early infusion compared to late infusion.
  • The difference in DCR remained significant after adjusting for disease stage, age, and ethnicity.
  • The adjusted odds ratio for higher DCR with early infusion was 1.18, suggesting a positive association.
  • Subgroup analyses indicated consistent results across sex, age, stage, and immune checkpoint inhibitor (ICI) agent.
  • Significant results were observed among non-Hispanic patients, while findings for Hispanic patients were inconclusive due to limited sample size.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

0 of 6
authors report competing interests
6 report none
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free